Immix Biopharma (NASDAQ:IMMX) Posts Earnings Results, Misses Expectations By $0.12 EPS

Immix Biopharma (NASDAQ:IMMX) posted its earnings results on Wednesday. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.12), FiscalAI reports.

Immix Biopharma Stock Performance

NASDAQ:IMMX traded down $0.57 during trading hours on Friday, reaching $8.15. The company’s stock had a trading volume of 750,582 shares, compared to its average volume of 889,096. The firm has a market capitalization of $431.62 million, a price-to-earnings ratio of -9.16 and a beta of 0.25. The firm has a 50-day simple moving average of $7.70 and a 200-day simple moving average of $5.20. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $11.61.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Immix Biopharma in the 4th quarter valued at about $386,000. KVP Capital Advisors LP purchased a new position in Immix Biopharma in the 4th quarter worth approximately $1,205,000. XTX Topco Ltd lifted its position in Immix Biopharma by 32.0% in the fourth quarter. XTX Topco Ltd now owns 46,394 shares of the company’s stock valued at $243,000 after purchasing an additional 11,241 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Immix Biopharma in the fourth quarter valued at approximately $116,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Immix Biopharma during the fourth quarter valued at approximately $1,773,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on IMMX shares. Citizens Jmp restated a “market outperform” rating and set a $23.00 price objective on shares of Immix Biopharma in a research report on Friday. HC Wainwright increased their target price on Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Morgan Stanley started coverage on Immix Biopharma in a research note on Wednesday. They set an “overweight” rating and a $20.00 price target for the company. Finally, Mizuho began coverage on Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.